Piperacillin-Tazobactam Dosing at CrCl 31 mL/min
For a patient with a creatinine clearance of 31 mL/min, administer piperacillin-tazobactam 2.25 grams every 6 hours for non-pneumonia infections, or 3.375 grams every 6 hours for nosocomial pneumonia, given as a 30-minute intravenous infusion. 1
FDA-Approved Dosing by Renal Function
The FDA drug label provides explicit dosing guidance based on creatinine clearance 1:
- CrCl 20-40 mL/min (which includes 31 mL/min):
- Standard infections: 2.25 g every 6 hours
- Nosocomial pneumonia: 3.375 g every 6 hours
This represents a dose reduction from the normal renal function regimen (3.375 g q6h or 4.5 g q6h) to account for decreased renal clearance and prevent drug accumulation.
Pharmacokinetic Rationale
At CrCl 31 mL/min, piperacillin clearance is significantly reduced. Research demonstrates that both piperacillin and tazobactam clearance correlate directly with renal function 2, 3. The single-dose pharmacokinetic study showed that total body clearance and area under the curve of both drugs correlate with creatinine clearance, with peak plasma concentrations increasing minimally as renal function declines 2.
Key consideration: Patients with moderately impaired renal function (CrCl 30-65 mL/min) actually achieve better target attainment than those with normal or augmented renal clearance 4. In one study, 100% of patients with CrCl <30 mL/min receiving twice-daily dosing reached therapeutic targets, compared to only 38% of patients with preserved renal function receiving three-times-daily dosing 4.
Extended Infusion Considerations
While the FDA label specifies 30-minute infusions, critical care guidelines suggest extended infusions (over 3-4 hours) or continuous infusions may optimize pharmacodynamic target attainment, particularly for severe infections 5, 6, 7. For β-lactams, achieving 100% time above MIC (T>MIC) is associated with optimal outcomes in severe infections 5, 6.
However, at CrCl 31 mL/min with standard dosing, most patients will achieve adequate exposure without extended infusions due to reduced clearance 4, 8.
Monitoring and Safety
Critical safety point: Patients with renal impairment are at increased risk for piperacillin accumulation and neurotoxicity 9, 10. One study found that the 4.5 g dose (even with reduced frequency) caused acute kidney injury in 25-38.5% of patients with renal impairment, compared to only 5.6% with the 2.25 g dose 9.
Monitor for:
- Signs of neurotoxicity (seizures, confusion, myoclonus) if trough concentrations exceed 361 mg/L 10
- Worsening renal function, particularly with higher doses
- Clinical response and consider therapeutic drug monitoring if available
Hemodialysis Adjustment
If the patient progresses to hemodialysis, dosing changes to 2.25 g every 12 hours (or every 8 hours for nosocomial pneumonia), with an additional 0.75 g dose after each dialysis session, as hemodialysis removes 30-40% of the administered dose 1, 2.